Sanofi prostate cancer drug shows 28 percent survival
Reviewed By
Rating
Sanofi prostate cancer drug shows 28 percent survival
Our Review Summary
This story is a basic restatement of information from a company spokesperson about the results of a study that have not even been presented, yet alone peer reviewed. The story didn’t comment at all on the observed tradeoff of 2.4 months in improved median survival versus a 3% higher risk of death from side effects. And, by the way, the headline is inaccurate. It wasn’t "28 percent survival" but a "28 percent survival advantage" – which still isn’t optimum because such a relative benefit number isn’t nearly as helpful as hearing the absolute numbers.
Why This Matters
This story never defined the patient population being studied. Prostate cancer is common in men, especially as they get older. However, not all prostate cancer requires treatment to decrease the chance of a man dying of prostate cancer. This story was irresponsible in not mentioning that this was a study of men with advanced prostate cancer – meaning that they already had prostate cancer that had spread beyond the prostate to be eligible to participate in the study.
Criteria
Not Satisfactory
The story included no discussion of costs. If a drug is this far down the pipeline in the EU and the US, somebody has some cost projections.
Satisfactory
The story included the mean overall improvement in survival. But it didn’t comment at all on the tradeoff of 2.4 months in improved median survival versus a 3% higher risk of death from side effects. A barely satisfactory grade on this.
Satisfactory
The story mentioned that:
- 4.9 percent of patients using cabazitaxel died from side-effects. Sanofi said this was mainly due to neutropenia, a blood disorder people can get from chemotherapy treatment, and its complications. This compared with 1.9 percent using mitoxantrone.
Not Satisfactory
The story is based on results that have not yet been presented as mentioned by a company spokesperson. The story made no comment on the limitations of what you can conclude from information given by a company that has not been presented, published or peer reviewed.
Not Satisfactory
The story engaged in disease mongering of a sort in that it failed to mention that this drug is being investigated for advanced prostate cancer, meaning metastatic disease, not for early-stage prostate cancer. Not all prostate cancers are equal and certainly not all become advanced or deadly.
Not Satisfactory
No independent sources were quoted to evaluate the claims made by the drug company.
Not Satisfactory
There was no comparison with other approaches other than the single other treatment in the study. This is an inadequate representation of the options for men managing advanced prostate cancer.
Satisfactory
The story indicated that the drug reported on was not yet approved for use in the EU; it also mentioned that drug is currently scheduled for an expedited review by the US FDA.
Not Applicable
Not applicable because no claims of novelty were made. Conversely, readers didn’t learn anything about what’s different and important about this drug in the way it works – if anything.
Not Satisfactory
Although we could not find a company press release, all of the info comes from a company spokesperson about results of a study yet to be presented. Is that any different than relying solely or largely on a news release?
Total Score: 3 of 9 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like